ReviewCureus2026
New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally, exhibiting marked diversity in clinical presentation, risk of progression, and response to therapy. Despite advances in understanding its pathophysiology, including the pivotal role of galactose-deficient IgA1 (Gd-IgA1), anti-Gd-IgA1 autoantibodies, and dysregulated mucosal and systemic immune responses, therapeutic options remain limited. This review provides a comprehensive overview of the current therapeutic landscape in IgAN, which is stratified into conservative care with renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and corticosteroids, and newer advances like the endothelin receptor antagonists, immunosuppressive agents, and targeted therapeutics. Through synthesizing evidence from recent clinical trials and ongoing studies, we aim to provide clinicians and researchers with a current and forward-looking perspective on therapeutic strategies in IgAN, emphasizing the shift from conservative therapy to targeted, individualized interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.